Mineral Sunscreen Formulation: Regulatory Compliance Across EU, US & China

Overview #

Mineral sunscreen is not a simple category. The regulatory picture across the EU, US, and China is genuinely fragmented — and the gaps between those three frameworks are wide enough to sink a product launch if you don’t plan for them early. We’ve had brand partners come to us with a finished formula, a packaging design, and a launch date, only to find out their ZnO concentration is fine for the US but triggers a notification requirement in China that adds four months to the timeline. That’s an expensive lesson. The goal here is to walk through what each market actually requires, where the real friction points are, and what documentation we prepare so your regulatory submission doesn’t stall.

Permitted UV Filter Limits by Market #

The first thing to understand is that ZnO and TiO₂ are not universally approved at the same concentrations. They’re not even classified the same way across markets.

In the EU, both zinc oxide and titanium dioxide are listed as approved UV filters under EU Cosmetics Regulation 1223/2009, Annex VI. ZnO is permitted up to 25% (as nanoparticles, with mandatory nano labeling). TiO₂ is permitted up to 25% as a UV filter — but the EU has separately restricted TiO₂ in spray/powder formats due to inhalation risk concerns, a restriction that came into force in 2022. If your product is a spray SPF, that’s a reformulation conversation, not a labeling fix.

In the US, the FDA classifies mineral UV filters as OTC drug active ingredients under the sunscreen monograph. ZnO is permitted up to 25%, TiO₂ up to 25%, individually or in combination. The FDA’s OTC framework means your formula must comply with the final monograph conditions — concentration, dosage form, labeling — and there’s no pre-market approval, but the compliance burden is real. The FDA Cosmetics Guidelines page is a starting point, but for sunscreen specifically you need to be reading the OTC Drug Monograph, not the cosmetics section.

China is the most demanding of the three. Under NMPA Cosmetic Regulation, mineral sunscreens are classified as “special use cosmetics,” which means mandatory registration — not just notification — before market entry. ZnO is permitted up to 25%, TiO₂ up to 25%. But the registration process requires a full safety assessment dossier, efficacy testing conducted at a NMPA-recognized lab, and a Chinese-language product label review. Timeline from submission to approval: typically 8–12 months for new registrations. We’ve seen it stretch to 14 months when the dossier has gaps.

One thing that doesn’t show up in that table: the EU nano labeling requirement is not optional and it’s not a technicality. If your ZnO particle size is below 100nm, the ingredient must appear on the INCI list as “Zinc Oxide (nano).” We’ve had batches rejected at the CPNP notification stage because the supplier’s particle size certificate wasn’t included in the dossier. We now require a D90 particle size report from every ZnO supplier before we finalize a formula for EU-bound products.

Safety Assessment Requirements #

This is usually where projects go sideways. Brands often treat the safety assessment as a box-ticking exercise. It isn’t.

For EU compliance, the safety assessment must follow the format defined in Annex I of Regulation 1223/2009 and be signed by a qualified safety assessor — typically a toxicologist with relevant credentials. The assessment covers both Part A (safety information: chemical characterization, toxicological profile, exposure assessment) and Part B (safety evaluation: the assessor’s professional judgment). For nano-form UV filters, the SCCS Scientific Opinion on ZnO nano and TiO₂ nano are the reference documents. The SCCS has issued opinions on both — ZnO nano is considered safe up to 25% in non-spray cosmetics; TiO₂ nano is considered safe in non-spray applications. Those opinions are the backbone of any EU safety dossier for mineral SPF.

For the US, there’s no mandatory pre-market safety assessment in the same formal sense. But if you’re selling an OTC sunscreen drug product, you need to be able to demonstrate that your formula meets the monograph conditions and that your SPF testing was conducted according to FDA-recognized methodology (ISO 24444:2019 for in vivo SPF, or the FDA’s own test method). We run SPF testing at ISO-accredited labs and include the full test report in the technical file.

China’s safety assessment requirement is the most document-intensive. The NMPA requires a toxicological safety assessment that includes: acute toxicity data, skin irritation/sensitization data, and — for products making SPF claims — in vivo SPF testing at a NMPA-recognized testing institution. The testing must be done on the final formula, in the final packaging. This is not a detail. We’ve had clients try to submit with testing done on a slightly different formula version and the NMPA rejected the dossier. The formula you test is the formula you register. Full stop.

One clinical reference worth knowing: a randomized, double-blind, split-face study (n=42, 12 weeks) comparing a 20% ZnO mineral sunscreen against a chemical UV filter benchmark showed equivalent photoprotection (SPF 30 ± 2.1 vs. SPF 31 ± 1.8) with statistically lower erythema scores at week 4 in the mineral arm. That kind of data is useful for brand positioning, but it also supports the safety narrative in a dossier — particularly for sensitive skin claims.

Labeling Requirements: Where the Details Kill You #

EU labeling for mineral SPF products must include: the SPF value (as a number and a category label — “Low,” “Medium,” “High,” “Very High”), UVA protection indication (the UVA circle logo or equivalent), water resistance claims only if substantiated by testing, and the nano notation in the INCI list where applicable. The “broad spectrum” language used in the US is not the EU standard — EU uses the UVA/UVB ratio framework.

US OTC sunscreen labeling is governed by the FDA monograph and has its own specific requirements: “Drug Facts” panel format, active ingredient declaration with percentage, directions for use (including reapplication interval — every 2 hours is the standard), and SPF value. “Broad Spectrum” is a permitted claim only if the product passes the FDA’s critical wavelength test (λc ≥ 370nm). Water resistance claims require substantiation at either 40 or 80 minutes. Honestly, the Drug Facts panel format trips up a lot of international brands who aren’t used to the OTC drug labeling framework.

China requires Chinese-language labeling as a hard requirement — no exceptions. The label must include the registration number once approved, the SPF value, PA rating (for UVA protection), and the product must not make drug-like claims. The PA system (PA+, PA++, PA+++, PA++++) is the Chinese UVA labeling standard, based on the PPD (Persistent Pigment Darkening) method. If you’re used to the EU UVA circle or the US “Broad Spectrum” language, the PA system requires separate testing and a different way of thinking about UVA claims.

For brands targeting all three markets simultaneously, we almost always recommend developing a master formula and then creating market-specific label variants. The formula can be identical; the label architecture has to be built separately for each market. This is not optional complexity — it’s the reality of selling mineral SPF globally.

Where Most Brands Get This Wrong #

The most common mistake we see: brands treat mineral sunscreen as a cosmetic everywhere. It isn’t. In the US it’s an OTC drug. In China it’s a special use cosmetic with registration requirements that function more like a drug approval than a cosmetic notification. Only in the EU does it sit cleanly in the cosmetic notification framework — and even there, the nano requirements add a layer most brands underestimate.

The second mistake is timeline planning. We’ve had brand partners budget 3 months for China registration. That’s not realistic. Even with a clean dossier, 8 months is optimistic. If the NMPA requests supplementary data — which happens in roughly 40% of first submissions in our experience — add another 2–3 months. Plan for 12 months minimum if China is in your launch roadmap.

The third mistake is formula lock. Brands sometimes want to finalize packaging before the formula is locked, or change the fragrance after safety testing is complete. In China, any formula change after registration submission means starting over. We push back hard on this. The formula that goes into safety testing is the formula that gets registered. We’ve rejected project timelines that didn’t account for this.

There’s also a cost dimension that doesn’t get discussed enough. NMPA registration for a special use cosmetic — including the required in-country testing, dossier preparation, and agency fees — typically runs $8,000–$15,000 USD per SKU. For a brand launching 3 mineral SPF SKUs into China simultaneously, that’s a meaningful line item before you’ve sold a single unit. Airless pump packaging, which is often specified for mineral SPF to prevent oxidation and contamination, adds $0.40–$0.80 per unit at MOQ 3,000. These are real numbers that belong in the business case, not surprises at the invoice stage.

We’re still not fully convinced that the EU’s approach to TiO₂ spray restrictions is settled science — the inhalation risk data for cosmetic spray formats is still evolving, and what’s acceptable today may shift. We tell brand partners building spray SPF lines for the EU to watch the SCCS opinions closely over the next 18–24 months.

For brands working on retinoid-containing SPF hybrids or vitamin C antioxidant combinations, the regulatory picture gets more complex — those actives add their own stability and labeling considerations on top of the UV filter framework.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a mineral SPF brief comes in. Because the answer changes everything — formula architecture, testing protocol, documentation package, and timeline.

If you’re launching in the EU only, we can move relatively quickly. CPNP notification is straightforward once the safety assessment is signed and the nano documentation is in order. Typical project timeline from brief to market-ready: 5–7 months including stability and SPF testing.

If China is in scope, we start the NMPA registration process in parallel with formula development — not after. Waiting until the formula is finalized to start the registration conversation costs you 3–4 months. We’ve learned this the hard way on behalf of clients who didn’t want to hear it early in the project.

For US OTC compliance, we build the Drug Facts panel into the label brief from day one and ensure SPF testing is conducted under FDA-recognized methodology. We’ve seen brands try to use EU SPF test data for US submissions — the FDA doesn’t accept it.

One thing we always flag: if your target SPF is 50+, the testing burden increases. The EU caps the on-pack claim at SPF 50+ regardless of measured value, but the US allows SPF 50 and SPF 100 as distinct claims with different testing requirements. Aligning on the SPF claim early prevents expensive retesting later.

Frequently Asked Questions #

Q: We want to launch in both the EU and China at the same time — is that realistic?

Technically yes, but the timelines don’t align naturally. EU notification can be done in 6–8 weeks once the dossier is ready; China registration takes 8–14 months. Most brands we work with soft-launch in the EU first, then enter China 9–12 months later. Running both processes in parallel from day one is the right approach — just don’t expect simultaneous launch dates.

Q: Our formula uses 18% ZnO — do we need nano labeling in the EU?

It depends on particle size, not concentration. If your ZnO D90 is below 100nm, yes — it must be listed as “Zinc Oxide (nano)” on the INCI. If your supplier is providing non-nano ZnO (D90 above 100nm), standard INCI notation applies. We require a particle size certificate from every ZnO supplier. Don’t assume — get the data.

Q: Can we use the same SPF test report for all three markets?

No. The EU uses ISO 24444:2019 for in vivo SPF. The FDA has its own test method (21 CFR 201.327). China requires testing at a NMPA-recognized institution using their specified protocol. Three markets, three test reports. Budget accordingly — in vivo SPF testing per market runs approximately $1,500–$3,000 USD per formula.

Q: We’ve heard China NMPA registration is getting faster — is that true?

There have been process improvements, and the NMPA has been working to reduce backlogs. In our recent submissions, we’ve seen some approvals come through closer to 8 months rather than 12. But we still plan for 12 months in every project timeline. The risk of planning for 8 and hitting 12 is worse than the reverse.

Q: Do we need a separate safety assessment for each market, or can one document cover all three?

You need market-specific documents, but a well-structured master safety dossier can be the foundation for all three. The EU requires the Annex I format signed by a qualified assessor. The US doesn’t mandate a specific format but you need the underlying data. China requires a Chinese-language safety assessment following NMPA guidelines. We build a master technical file and then produce market-specific derivatives — it’s more efficient than starting from scratch three times.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.